The announcement was welcome news for those with major depressive disorder, affecting an estimated 8.3% of the adult ...

Even light-intensity activities such as walking can reduce one’s risk for clinical depression. So, what are the most common ...

The Food and Drug Administration has approved the first-ever stand-alone nasal spray to treat drug-resistant depression.

Johnson & Johnson has announced the FDA’s approval of a first-of-its-kind, esketamine nasal spray called Spravato for the ...

The nasal spray Spravato, which is made from the drug esketamine, had been approved in 2019 for patients who failed to ...

The U.S. Food and Drug Administration has approved a nose spray to help treat depression, Johnson & Johnson announced Tuesday ...

An emerging treatment for clinical depression has reached an important milestone. This week, the Food and Drug Administration ...

Here's what MDs want you to know about Spravato, the latest FDA-approved standalone nasal spray for depression.

Using computational models, the researchers studied how the brain's reward-learning system functions in those with depression, especially among individuals experiencing anhedonia, the inability to ...

Johnson & Johnson's Spravato nasal spray has been FDA-approved as a stand-alone therapy for adults with treatment-resistant ...

The TGA has issued a requirement for new warnings to be provided with the drug montelukast, commonly used to treat asthma and ...

The U.S. Food and Drug Administration has approved a nasal spray that is known to help treat depression.